about
Comparing the clinical effectiveness of different new-born hearing screening strategies. A decision analysis.Assessing the Costs and Cost-Effectiveness of Genomic SequencingOncotyrol--Center for Personalized Cancer Medicine: Methods and Applications of Health Technology Assessment and Outcomes Research.The burden of chronic mercury intoxication in artisanal small-scale gold mining in Zimbabwe: data availability and preliminary estimates.Economic evaluation of newborn hearing screening: modelling costs and outcomes.A bias-adjusted evidence synthesis of RCT and observational data: the case of total hip replacement.Endovascular optical coherence tomography ex vivo: venous wall anatomy and tissue alterations after endovenous therapy.Mercury as a serious health hazard for children in gold mining areas.Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials.Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics andBreast cancer incidence and mortality in Tyrol/Austria after fifteen years of opportunistic mammography screening.Personalized medicine in Europe: not yet personal enough?Mercury exposure in female artisanal small-scale gold miners (ASGM) in Mongolia: An analysis of human biomonitoring (HBM) data from 2008.Introduction of organised mammography screening in Tyrol: results of a one-year pilot phaseBenefits and harms of prostate cancer screening - predictions of the ONCOTYROL prostate cancer outcome and policy model.Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008.Applicability of two mobile analysers for mercury in urine in small-scale gold mining areas.EBM, HTA, and CER: clearing the confusionPrognostic value, clinical effectiveness and cost-effectiveness of high sensitivity C-reactive protein as a marker in primary prevention of major cardiac eventsMeasurement of fractional flow reserve to guide decisions for percutaneous coronary interventionUsing decision-analytic modelling to transfer international evidence from health technology assessment to the context of the German health care system.Assessment of effectiveness and cost-effectiveness of HPV testing in primary screening for cervical.Screening of the hearing of newborns - Update.Efficacy, routine effectiveness, and safety of horsechestnut seed extract in the treatment of chronic venous insufficiency. A meta-analysis of randomized controlled trials and large observational studies.Recall responses to tetanus and diphtheria vaccination are frequently insufficient in elderly persons.Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy.Individual health servicesDiagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis.Concepts of 'personalization' in personalized medicine: implications for economic evaluation.Use of DALYs in economic analyses on interventions for infectious diseases: a systematic reviewCommunicating the parameter uncertainty in the IQWiG efficiency frontier to decision-makers.Systematic assessment of decision models in Parkinson's disease.Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma TherapeuticsA preliminary study on health effects in villagers exposed to mercury in a small-scale artisanal gold mining area in Indonesia.Cost-effectiveness analysis in the assessment of diagnostic imaging technologies.Economic burden of osteoporotic fractures in Austria.Gender differences in the association between grip strength and mortality in older adults: results from the KORA-age study.Cost-Effectiveness Models in Breast Cancer Screening in the General Population: A Systematic Review.Signs and symptoms of mercury-exposed gold miners.Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria.
P50
Q24804934-52E19484-4795-4CE1-B059-63ECAB9AF713Q26774155-FB86894C-2732-471C-BB16-F01339609844Q30378973-C96091F3-4862-4F62-9B5F-7BFE48FACBC1Q30389812-924DCC45-0F19-4E9B-B2DA-B7BEC9CFCF8FQ30487995-21F9D152-B5E6-4E10-8D19-7CBC97DE3729Q31158042-0DE2D61F-3FCB-4093-880C-EB5F25495ED8Q33272783-0D9221F8-798A-4F06-8A99-2074C802DF55Q33322622-FEBE93D0-B16A-4C19-AE85-0219B46DBA1BQ33392652-D758D50E-4074-4994-8C58-F9D41BB51AAAQ33501851-347B94F3-28DF-47C9-968B-B52567CCCB6FQ33532804-50371B20-9CA4-4DAE-B93C-C738CEBA1A16Q33577079-04223CF2-DE2E-4DEE-850B-ED245D9AB2DDQ33779748-455A8B04-9969-4B6E-BA60-8911B45A24D6Q33816343-AA65B18B-07D1-44E7-B7A4-A1C93326A9E1Q33836709-389B8F7F-2E98-49A4-ADF2-FD26619BD55FQ33935048-8AA425E7-E4C7-49AD-A655-ECC1478A4916Q33980914-4DDF1A95-EB12-4595-8D87-384E3037DAC5Q34122716-711B18F7-F34C-4318-B9DF-446E82BF9E0FQ34445351-2AE2205A-21BB-45B0-9E2D-59DFA66BA04AQ34445454-62C16873-B0EB-4042-A589-779691C04C30Q34445478-F799B139-1CAC-4A2D-9D7F-25C94B02DD31Q34445534-0D7A82E9-B8BA-4CD3-A586-9913096AD54DQ34445607-1DCBDABE-58A0-4317-A01F-B85C59A6D1F2Q35041202-CB345186-7D08-41C4-AC9A-637D78908072Q35070671-D7B76DCB-82A9-40CA-B838-C8F0253B2E97Q35205445-7B1C8654-0527-448D-A68A-E5C8AB5C7386Q35237403-84E0E1DF-3F92-4EBF-8ED4-83978FAA1A3AQ35554481-E4D33CA9-BD01-46FF-B57A-9182BF61FBF6Q35575935-73D9216F-66C1-4443-8548-DCA08C7B190AQ35686520-C689C389-8BCD-4CE0-B61B-2CB4FDDA03E5Q35810381-A574386F-3165-4CAB-8BDC-27C849B013C0Q35887508-74353B07-C5B4-4C73-BDAA-F444A659302DQ35944156-65AD39F8-355B-4EFA-BA92-02F11995A836Q36016542-A231C3C2-121A-4D19-ADD8-5640612C032DQ36109458-15F872A8-9F4D-4ACD-A6B9-055D8F702705Q36175688-7B1E2C3D-DBA4-4762-B351-2E04457C65B2Q36208463-8602FB09-94C7-42D2-828D-5A9D8C66DA55Q36276324-572641C2-232C-4B3C-8099-64C4A3F06BD9Q36331278-1005609B-BEF3-48FF-8655-CD4C1AC028C8Q36339076-7F684ED8-6124-4B2A-BF02-C9D7312C51E7
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Uwe Siebert
@ast
Uwe Siebert
@en
Uwe Siebert
@es
Uwe Siebert
@nl
type
label
Uwe Siebert
@ast
Uwe Siebert
@en
Uwe Siebert
@es
Uwe Siebert
@nl
prefLabel
Uwe Siebert
@ast
Uwe Siebert
@en
Uwe Siebert
@es
Uwe Siebert
@nl
P106
P31
P496
0000-0001-6425-7671